Ata Dtc Dynamic Risk

ATA DTC Dynamic Risk Stratification Tool

Source: 2015 ATA Management Guidelines — Response-to-Therapy Classification (Table 13) and Recommendations 56–62.
Haugen et al. Thyroid 2016;26(1). DOI: 10.1089/thy.2015.0020

CONCEPT

The initial ATA risk tier (Low/Intermediate/High) is a static estimate at surgery. Over time, the patient's actual disease status is better predicted by their response to therapy — how Tg, imaging, and anti-Tg antibodies evolve after treatment.

Dynamic reclassification replaces the initial tier as the primary driver of:

• TSH suppression targets
• Follow-up frequency and modality
• Need for further therapy

STEP 1 — Timing of Reclassification

Data needed for reclassification:

• Neck ultrasound (thyroid bed + central + lateral nodes)
• Serum Tg (on suppression OR stimulated if appropriate)
• Anti-Tg antibodies (essential — interferes with Tg interpretation)
• Any additional imaging if clinically indicated

STEP 2 — Classify the Response to Therapy

✅ EXCELLENT RESPONSE

Criteria:

• Negative structural and functional imaging (negative neck US, negative whole body scan if performed)
• AND suppressed Tg <0.2 ng/mL (on levothyroxine suppression)
• OR stimulated Tg <1 ng/mL (after withdrawal or rhTSH)
• Anti-Tg antibodies undetectable or decreasing to undetectable

Clinical implications:

• Recurrence risk: ~1–4%
• TSH target: relax to low-normal (0.5–2.0 mU/L) for all initial risk tiers → low/intermediate risk patients can be managed as euthyroid
• Follow-up: reduce intensity — annual clinical exam + TSH/Tg measurement; periodic neck US
• No further RAI or additional imaging needed unless new symptoms develop

📈 BIOCHEMICAL INCOMPLETE RESPONSE

Criteria:

• Negative structural and functional imaging (no structural disease)
• BUT suppressed Tg ≥1 ng/mL OR stimulated Tg ≥10 ng/mL
• OR persistently rising anti-Tg antibodies (even with undetectable Tg)

Clinical implications:

• Recurrence risk: ~20% (most are clinically insignificant or spontaneously resolve)
• ~30% will develop structural disease; ~20% achieve excellent response without further therapy
• Management options:
  • Continue observation with serial Tg + anti-Tg + neck US every 6–12 months
  • Maintain TSH suppression (target TSH 0.1–0.5 mU/L for intermediate; <0.1 for high)
  • Consider RAI only if Tg rising significantly (not for stable or declining Tg)
  • Additional anatomic/functional imaging if Tg acceleration: CT neck/chest, FDG-PET if Tg >10 with negative WBS

🏗️ STRUCTURAL INCOMPLETE RESPONSE

Criteria:

• Structural or functional evidence of disease persists or is newly identified
• Includes: persistent/new lymph nodes on US, residual uptake on WBS, distant metastases on CT/MRI/PET
• Tg may be detectable OR undetectable (FDG-avid, RAI-negative disease can have low/undetectable Tg)

Clinical implications:

• Recurrence risk: ~50–85% depending on lesion site and characteristics
• Disease-specific mortality 11% for locoregional; up to 57% for distant mets
• Management:
  • Additional therapy guided by lesion type, location, size, and pace of progression:
    • Locoregional resectable disease → surgical re-excision
    • RAI-avid distant disease → RAI treatment
    • RAI-refractory disease → kinase inhibitor therapy (sorafenib, lenvatinib)
    • Slow-growing, asymptomatic distant mets → active surveillance acceptable
  • Maintain aggressive TSH suppression (TSH <0.1 mU/L) while structural disease present
  • Multidisciplinary review recommended for high-volume or metastatic cases

❓ INDETERMINATE RESPONSE

Criteria (any one of the following):

• Nonspecific findings on structural imaging (non-specific US changes, stable non-enlarged nodes)
• Faint/equivocal RAI uptake in thyroid bed
• Suppressed Tg detectable but <1 ng/mL (not clearly excellent)
• Stimulated Tg detectable but <10 ng/mL
• Anti-Tg antibodies stable or declining (not rising, not yet undetectable)

Clinical implications:

• Recurrence risk: ~15–20%
• Most indeterminate responses will evolve to excellent or structural over time with serial observation
• Management:
  • Continue surveillance with serial neck US + Tg every 6–12 months
  • TSH target: low-normal to slightly suppressed (0.1–0.5 mU/L for intermediate; 0.5–2 for low risk)
  • Additional imaging (CT, FDG-PET) if Tg trending upward or new symptoms
  • Do NOT escalate to additional RAI or surgery without structural evidence of disease

STEP 3 — Map Response to Ongoing TSH Suppression Target

Benefits of TSH suppression must be weighed against harms (AF, osteoporosis, adrenergic symptoms) especially in elderly, postmenopausal women, and patients with CV disease.

STEP 4 — Reclassification Is Iterative

Dynamic risk reclassification is not a one-time event — repeat at each follow-up visit:

Initial ATA Risk Tier (post-surgery)
        ↓
First Response Assessment (6–24 months)
        ↓
[Excellent] → Reduce follow-up intensity, relax TSH suppression
[Biochemical incomplete] → Serial Tg/imaging; suppress TSH; consider further workup
[Structural incomplete] → Additional therapy decision; MDT review
[Indeterminate] → Continue surveillance; follow Tg trend
        ↓
Re-evaluate at each visit → Update category → Adjust management

CLINICAL GUARDRAILS

• Anti-Tg must be checked every time — positive anti-Tg invalidates Tg interpretation; track anti-Tg trend as a surrogate marker instead
• Suppressed Tg <0.2 on LT4 is not the same as stimulated Tg <1 — both are criteria for excellent response, but use one or the other consistently; don't mix thresholds
• Rising anti-Tg = biochemical incomplete — even with undetectable Tg, rising anti-Tg signals disease activity and should be managed as biochemical incomplete
• "Indeterminate" is not "all clear" — it requires continued follow-up; do not reassign to excellent without meeting all criteria
• Structural incomplete with slow growth does not always mandate immediate escalation — pace of growth and lesion characteristics guide urgency; active surveillance is reasonable for small, slowly growing, asymptomatic distant lung metastases
• FDG-PET/CT should be considered when: Tg is rising but RAI WBS is negative (RAI-refractory disease), or when structural disease is clinically suspected but conventional imaging is inconclusive
• Relax TSH suppression in excellent responders — unnecessary chronic TSH suppression carries cardiovascular and bone risks; excellent response justifies moving to euthyroid range even in initially high-risk patients